Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2162)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 09.05.24 15:58:22 von
neuester Beitrag 09.05.24 15:58:22 von
Beiträge: 22.864
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 4
Gesamt: 1.234.446
Gesamt: 1.234.446
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVAX
4,1985
EUR
+0,80 %
+0,0335 EUR
Letzter Kurs 09.05.24 Tradegate
Neuigkeiten
01.05.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
3,2000 | +93,94 | |
1,0800 | +44,12 | |
1,3300 | +30,51 | |
1,9950 | +27,48 | |
21,010 | +26,80 |
Wertpapier | Kurs | Perf. % |
---|---|---|
7,5000 | -20,97 | |
2,4650 | -27,50 | |
4,7000 | -41,10 | |
2,0300 | -51,55 | |
5,7700 | -60,64 |
Beitrag zu dieser Diskussion schreiben
Die USA werden vermutlich versuchen alles was nur in die Nähe eines Impfstoffes kommt aufzukaufen. Ist nur eine Frage der Zeit wann die meistens Kurse wie Novavax nach oben ausbrechen.
Übernahmekandidat für Sanofi in meinen Augen:
Novavax plans FDA filing after NanoFlu trumps Sanofi flu vaccine
26th March 2020
Image
by
Anna Smith
Novavax has unveiled new Phase III data showing that its recombinant quadrivalent seasonal influenza vaccine candidate, NanoFlu, met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent.
As a results of the successful data, the company has announced plans to submit a filing to the US Food and Drug Administration (FDA) under the agency's accelerated approval pathway.
In the trial, geometric mean titers (GMT) at day 28 for NanoFlu were 24% to 66% higher than for Fluzone Quadrivalent, while the experimental vaccine was associated with 11.4 to 20.4 higher seroconversion rates (SCR) percentage points than the Sanofi drug.
Top-line results showed that NanoFlu achieved the primary endpoints, using both GMT and SCR, for all four strains included in the vaccine, as measured by haemagglutination inhibition (HAI) assays using egg-derived reagents.
According to the company, NanoFlu was also well tolerated in the Phase III study and had a safety profile comparable to Fluzone Quadrivalent, but was associated "with a modest increase in local adverse events."
Last year Novavax announced that its respiratory syncytial virus vaccine ResVax failed to hit its main goal, despite showing efficacy against a secondary objective, preventing RSV LRTI hospitalisations by 44%.
Share
Novavax plans FDA filing after NanoFlu trumps Sanofi flu vaccine
26th March 2020
Image
by
Anna Smith
Novavax has unveiled new Phase III data showing that its recombinant quadrivalent seasonal influenza vaccine candidate, NanoFlu, met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent.
As a results of the successful data, the company has announced plans to submit a filing to the US Food and Drug Administration (FDA) under the agency's accelerated approval pathway.
In the trial, geometric mean titers (GMT) at day 28 for NanoFlu were 24% to 66% higher than for Fluzone Quadrivalent, while the experimental vaccine was associated with 11.4 to 20.4 higher seroconversion rates (SCR) percentage points than the Sanofi drug.
Top-line results showed that NanoFlu achieved the primary endpoints, using both GMT and SCR, for all four strains included in the vaccine, as measured by haemagglutination inhibition (HAI) assays using egg-derived reagents.
According to the company, NanoFlu was also well tolerated in the Phase III study and had a safety profile comparable to Fluzone Quadrivalent, but was associated "with a modest increase in local adverse events."
Last year Novavax announced that its respiratory syncytial virus vaccine ResVax failed to hit its main goal, despite showing efficacy against a secondary objective, preventing RSV LRTI hospitalisations by 44%.
Share
Es wird nicht nur ein Unternehmen zum Zuge kommen, die benötigiten Mengen wird ein Unternehmen nicht stemmen können, da werden mehrere profitieren und hoffentlich bald einen Impfstoff präsentieren!
Antwort auf Beitrag Nr.: 63.129.127 von Zukunftsaussicht am 25.03.20 16:24:33
Bin in
IBio
Novavax
Biocept und
Inovio drin.
Hoffentlich ist ein guter Gaul im Stall dabei ( oder auch Mehrere )
Zitat von Zukunftsaussicht: Ich bin gespannt wer das Rennen für den Impfstoff macht, ich bin in 3 verschiedenen Unternehmen investiert.
Wobei ich die Chancen für BioNTech am besten einschätze.
Was meint Ihr und wo seit ihr noch drin?
Bin in
IBio
Novavax
Biocept und
Inovio drin.
Hoffentlich ist ein guter Gaul im Stall dabei ( oder auch Mehrere )
Ich bin gespannt wer das Rennen für den Impfstoff macht, ich bin in 3 verschiedenen Unternehmen investiert.
Wobei ich die Chancen für BioNTech am besten einschätze.
Was meint Ihr und wo seit ihr noch drin?
Wobei ich die Chancen für BioNTech am besten einschätze.
Was meint Ihr und wo seit ihr noch drin?
So, nachgekauft, jetzt kann die Wende kommen... Gern bis 18 Euro 😂. Gerade die Amerikaner sind verzweifelt und verrückt, da geht was.... 😉
Antwort auf Beitrag Nr.: 63.127.396 von Magnetfeldfredy am 25.03.20 13:58:51Dann bin ich gespannt wie drüben reagiert wird und wie hoch es heute geht...
Einen hab ich noch, geil:
Novavax price target raised to $23 from $16 at Cantor Fitzgerald
Read more at:
https://thefly.com/landingPageNews.php?id=3059696
Novavax price target raised to $23 from $16 at Cantor Fitzgerald
Read more at:
https://thefly.com/landingPageNews.php?id=3059696
Nach positiven Phase III Daten, best in class for Grippe Impfung weltweit und für Corona-Impfung prädestiniert:
Novavax price target raised to $24 from $17 at H.C. Wainwright 07:26 NVAX H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Novavax to $24 from $17 and reiterates a Buy rating on the shares. The stock closed Tuesday up 19% to $12.77. Novavax yesterday announced positive top-line results from its pivotal Phase 3 clinical trial with NanoFlu, the company's Matrix-M adjuvanted recombinant quadrivalent seasonal influenza vaccine candidate for adults aged 65 and older, Bernardino tells investors in a research note. The results are impressive, as they clearly show better immunogenic responses are stimulated by NanoFlu versus the market-leading quadrivalent seasonal influenza vaccine, says the analyst. Bernardino believes the data create a clear path to FDA licensure.
Read more at:
https://thefly.com/landingPageNews.php?id=3059689
Novavax price target raised to $24 from $17 at H.C. Wainwright 07:26 NVAX H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Novavax to $24 from $17 and reiterates a Buy rating on the shares. The stock closed Tuesday up 19% to $12.77. Novavax yesterday announced positive top-line results from its pivotal Phase 3 clinical trial with NanoFlu, the company's Matrix-M adjuvanted recombinant quadrivalent seasonal influenza vaccine candidate for adults aged 65 and older, Bernardino tells investors in a research note. The results are impressive, as they clearly show better immunogenic responses are stimulated by NanoFlu versus the market-leading quadrivalent seasonal influenza vaccine, says the analyst. Bernardino believes the data create a clear path to FDA licensure.
Read more at:
https://thefly.com/landingPageNews.php?id=3059689
Novavax (NVAX) PT Raised to $24 at Ladenburg Thalmann, Following Report Of NanoFlu Achieving All Primary Endpoints In Phase 3 Clinical Trial
March 24, 2020 2:14 PM EDT Send to a Friend
Ladenburg Thalmann analyst Michael Higgins ...
This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
March 24, 2020 2:14 PM EDT Send to a Friend
Ladenburg Thalmann analyst Michael Higgins ...
This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |